PT - JOURNAL ARTICLE AU - Reingruber, Jürgen AU - Papale, Andrea AU - Holcman, David TI - Monitoring and predicting SARS-CoV-2 epidemic in France after deconfinement using a multiscale age-dependent rate model AID - 10.1101/2020.05.15.20099465 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.15.20099465 4099 - http://medrxiv.org/content/early/2020/05/20/2020.05.15.20099465.short 4100 - http://medrxiv.org/content/early/2020/05/20/2020.05.15.20099465.full AB - The entire world and France were strongly impacted by the SARS-COV-2 epidemic. Finding appropriate measures that effectively contain the spread of the epidemic without putting a too severe pressure on social and economic life is a major challenge for modern predictive approaches. To assess the impact of confinement (March 17th till May 11th) and deconfinement, we develop a novel rate model to monitor and predict the spread of the epidemic and its impact on the health care system. The model accounts for age-dependent interactions between population groups and predicts consequences for various infection categories such as number of infected, hospitalized, load of intensive care units (ICU), number of death, recovered from hospitalization and more. We use online health care data for the five most infected regions of France to calibrate the model. At day of deconfinement (May 11th), we find that 13% (around 4.8M) of the population is infected in the five most affected regions of France (extrapolating to 5.8M for France). The model predicts that if the reproduction number R0 is reduced by at least a factor of 2.5-3 for all age groups after deconfinement, which could be achieved by wearing masks and social distancing, a significant second peak can be prevented. However, if the reduction in R0 for the age group 0-25 would be less and below 2 (e.g. due to school openings), a second peak with ICU saturation is unavoidable. In that context, we argue that testing should be focused on children, but without tracing it will nevertheless have only a very limited impact on reducing the spread.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo fundingAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yespublic data available online (see url below) https://www.data.gouv.fr/fr/datasets/donnees-hospitalieres-relatives-a-lepidemie-de-covid-19/ https://geodes.santepubliquefrance.fr/\#c=news